A Look At FactSet Research Systems (FDS) Valuation After Recent Share Price Strength

FactSet Research Systems Inc.

FactSet Research Systems Inc.

FDS

0.00

What recent performance says about FactSet Research Systems (FDS)

FactSet Research Systems (FDS) has drawn attention after a recent share price move, with the stock up about 0.4% over the past day and 2.8% over the past week.

Over the past month the stock shows an 11.2% gain, while the past 3 months reflect a 16.0% decline and the 1 year total return stands at a 42.8% decline. This sets a different context for the recent strength.

For context, the latest share price of $232.73 sits alongside a 30 day share price return of 11.2%, while the 1 year total shareholder return reflects a 42.8% decline. This suggests that recent momentum contrasts with a weaker longer term experience.

If this shift in sentiment has you rethinking your portfolio, it may be worth scanning for other opportunities using our screener of 19 top founder-led companies

FactSet now trades at $232.73 with an estimated intrinsic discount of 37.2% and an 8.5% gap to the average analyst price target. So are you looking at an undervalued compounder, or has the market already priced in future growth?

Most Popular Narrative: 25.9% Undervalued

Based on the most followed narrative, FactSet Research Systems' fair value of $313.99 sits well above the recent $232.73 close, which puts the current discount in focus.

At the current price of ~210 USD, the market is valuing FactSet as a certain victim of generative AI (“SaaSPocalypse”), completely ignoring the company’s structural transformation over the last 5 years. FactSet no longer sells just access to stock prices (which can be commoditized); it sells operational infrastructure built on four strategic pillars that are extremely hard for a chatbot to replace: Cobalt (Private Markets), CUSIP (Global Standards), Vermilion (Reporting), and Portware (Execution).

Want to understand why this narrative still sees upside at a higher fair value? The entire case leans on compound earnings power, resilient margins, and a future profit multiple that might surprise you.

Result: Fair Value of $313.99 (UNDERVALUED)

However, this hinges on CUSIP, Cobalt and the wider platform keeping their relevance, and on AI, regulation or competitors not eroding those high margin, workflow advantages.

Another way of looking at value

There is a twist when you look at FactSet through its P/E. The current 14.4x multiple is above the fair ratio of 13.2x, yet sits well below peers at 25.8x and the wider US Capital Markets group at 42x. That mix can point to both upside potential and downside risk. Which side matters more to you?

To weigh that trade off with hard numbers instead of headlines, take a look at our valuation breakdown using this earnings multiple, including how it could move toward the fair ratio over time, in the See what the numbers say about this price — find out in our valuation breakdown.

NYSE:FDS P/E Ratio as at Apr 2026
NYSE:FDS P/E Ratio as at Apr 2026

Next Steps

With sentiment split between opportunity and risk, it helps to move quickly and test the numbers for yourself so you are not relying on headlines alone. Start by weighing the 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If this analysis has sharpened your thinking, do not stop at one company. Broaden your watchlist with ideas that fit different goals and risk levels.

  • Target potential mispricings by scanning companies that pass quality checks yet still trade on attractive valuations using our 60 high quality undervalued stocks.
  • Strengthen your income focus by reviewing businesses that pair higher yields with resilience in our 12 dividend fortresses.
  • Prioritise capital preservation by checking companies that score well on financial robustness and volatility using the 71 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.